Owkin Company

Owkin is a French-American startup that specializes in AI and federated learning for medical research. It was co-founded in 2016 by Dr Thomas Clozel M.D., a clinical research doctor and former assistant professor in clinical hematology, and Dr Gilles Wainrib, Ph.D., a pioneer in the field of artificial intelligence in biology. Owkin has recently published groundbreaking research at the frontier of AI and medicine in Nature Medicine, Nature Communications and Hepatology. The Owkin Platform connects life science companies with world-class academic researchers and hospitals to share deep medical insights for drug discovery and development. Using federated learning and breakthrough collaborative AI technology, Owkin enables its partners to unlock siloed datasets while protecting patient privacy and securing proprietary data. Through sharing high-value insights, the company powers unprecedented collaboration to improve patient outcomes. Owkin has raised $255M investment from life science companies and prominent VC funds and is now working with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Key achievements to date include HealthChain and MELLODDY; two Owkin led federated learning consortia fueling unprecedented collaboration in academic research and drug discovery, respectively.
Technology: Artificial Intelligence, Biotechnology, Clinical Trials, Machine Learning, Software
Industry: End-to-end Drug Development
Headquarters: New York, New York, United States
Founded Date: 2016-05-25
Employees Number: 101-250
Funding Status: Early Stage Venture
Investors Number: 15
Total Funding: 254100000
Estimated Revenue: $10M to $50M
Last Funding Date: 2021-11-18
Last Funding Type: Corporate Round

Visit Website
Register and Claim Ownership